BACKGROUND AND PURPOSE: Previous cost-effectiveness analyses analyzed warfarin
for stroke prevention in randomized trial settings. Given the complexities of warfarin …

Introduction: Atrial fibrillation (AF) increases the risk of ischemic stroke 5‐fold and may not
only be responsible for as many as 15% of all strokes that occur but also for larger and more …

Background and Purpose—In controlled trials, anticoagulation with warfarin reduces stroke
risk by nearly two thirds, but the benefit has been less pronounced in clinical practice. This …

Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …

Background Clinical guidelines are needed on whether or not to use anticoagulant therapy
to prevent stroke in patients with non-valvular atrial fibrillation. We did a Markov decision …

Background and Purpose—A number of clinical trials have shown the value of
anticoagulating patients with nonrheumatic atrial fibrillation to prevent ischemic stroke. The …

Background: Guidelines recommend warfarin use in patients with atrial fibrillation solely on
the basis of risk for ischemic stroke without antithrombotic therapy. These guidelines rely on …

Background and Purpose—Stroke outcomes in patients with atrial fibrillation (AF) tend to be
worse than those in patients without AF. The objective of this study was to evaluate whether …

Background and Purpose—Clinical trials have illustrated warfarin's protective effect on
stroke risk in patients with atrial fibrillation (AF). The current study investigated temporal …

Background: Patients with nonvalvular atrial fibrillation (NVAF) have often been excluded
from long-term anticoagulant trials, and therefore patients in clinical practice may have …